Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO
Follow-Up May Explain Lower Cytopenias, KOL Says
Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy.
